Asunercept
Clinical Development in Two Indications
Our lead immuno-oncology candidate asunercept is in clinical development for the treatment of solid tumors and malignant hematological diseases. It has shown significant improvements in progression-free survival and quality of life as well as a positive trend in overall survival in a controlled phase II proof-of-concept trial in recurrent glioblastoma. In a phase I trial in myelodysplastic syndromes (MDS), treatment with asunercept led to a decrease in transfusion frquency in 40 percent of patients during the duration of the trial.
Technology
The Apogenix team has created the HERA-ligand technology platform for the development of novel receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These fusion proteins offer clear advantages over other biologics such as antibodies and have the potential for broad application in oncology.
News
December 5, 2019
Apogenix to Present New Data on Asunercept at ESMO Immuno-Oncology Congress
November 7, 2019
Strong Quality of Life Data for Apogenix’ Asunercept Published in Journal of Neuro-Oncology